Oric Pharmaceuticals, Inc. (ORIC) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "ORIC"
      ],
      "issuer_cik": "0001796280",
      "owner_cik": "0001695028",
      "accession_number": "0001695028-26-000012",
      "form_type": "4",
      "filing_date": "2026-10-21",
      "period_of_report": "2026-10-20",
      "issuer_name": "Oric Pharmaceuticals, Inc.",
      "issuer_trading_symbol": "ORIC",
      "owner_name": "Piscitelli Dominic",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "Chief Financial Officer",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-20",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 14000,
      "transaction_price_per_share": 13.5279,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 69828,
      "transaction_value": 189390.6,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026."
        },
        {
          "id": "F2",
          "description": "Represents the weighted average share price of an aggregate total of 14,000 shares sold in the price range of $13.50 to $13.65 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."
        }
      ]
    },
    {
      "tickers": [
        "ORIC"
      ],
      "issuer_cik": "0001796280",
      "owner_cik": "0001584759",
      "accession_number": "0001584759-26-000017",
      "form_type": "4",
      "filing_date": "2026-10-02",
      "period_of_report": "2026-10-01",
      "issuer_name": "Oric Pharmaceuticals, Inc.",
      "issuer_trading_symbol": "ORIC",
      "owner_name": "Heyman Richard A.",
      "is_director": true,
      "is_officer": false,
      "is_ten_percent_owner": false,
      "is_other": false,
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-01",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 3200,
      "transaction_price_per_share": 12.9141,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 203472,
      "transaction_value": 41325.119999999995,
      "direct_or_indirect": "I",
      "nature_of_ownership": "See footnote",
      "footnotes": [
        {
          "id": "F1",
          "description": "The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC."
        },
        {
          "id": "F2",
          "description": "This transaction was executed in multiple trades at prices ranging from $12.57 to $13.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."
        },
        {
          "id": "F3",
          "description": "The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares."
        }
      ]
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.